TY - JOUR KW - Antigen-Presenting Cells KW - Antigens, Bacterial KW - Antigens, Viral KW - Herpesvirus 4, Human KW - Humans KW - Interferon-gamma KW - leprosy KW - Mycobacterium leprae AU - Lindh J AU - Anderson U AU - Britton S AU - De Ley M AB -

The number of gamma-interferon producing cells in the peripheral blood of leprosy (LL and BT) patients and controls was studied by the reversed protein A plaque assay before and after exposure in vitro to Mycobacterium leprae bacilli and Epstein-Barr virus (EBV). The level of spontaneous gamma-interferon production was significantly higher in BT patients compared to LL patients and controls. Mycobacterium leprae induced a specific gamma-interferon response in lymphocytes from BT patients and from healthy contacts whereas in LL patients and non-exposed controls the response was low or non-existing. There were no significant differences in the gamma-interferon response to EBV between the above groups.

BT - Clinical and experimental immunology C1 - http://www.ncbi.nlm.nih.gov/pubmed/3040308?dopt=Abstract DA - 1987 Jan IS - 1 J2 - Clin. Exp. Immunol. LA - eng N2 -

The number of gamma-interferon producing cells in the peripheral blood of leprosy (LL and BT) patients and controls was studied by the reversed protein A plaque assay before and after exposure in vitro to Mycobacterium leprae bacilli and Epstein-Barr virus (EBV). The level of spontaneous gamma-interferon production was significantly higher in BT patients compared to LL patients and controls. Mycobacterium leprae induced a specific gamma-interferon response in lymphocytes from BT patients and from healthy contacts whereas in LL patients and non-exposed controls the response was low or non-existing. There were no significant differences in the gamma-interferon response to EBV between the above groups.

PY - 1987 SP - 51 EP - 4 T2 - Clinical and experimental immunology TI - A single cell assay for the study of gamma-interferon formation in leprosy patients. UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1542566/pdf/clinexpimmunol00112-0060.pdf VL - 67 SN - 0009-9104 ER -